OmniAb (OABI) Current Deferred Revenue (2021 - 2026)
OmniAb (OABI) posted quarterly Current Deferred Revenue of $2.9 million for Q1 2026, up 70.39% year-over-year from $1.7 million in Q1 2025, and down 6.96% quarter-over-quarter from $3.2 million in Q4 2025.
OmniAb (OABI) Current Deferred Revenue (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Current Deferred Revenue for 6 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue rose 70.39% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (up 70.39% YoY), while the FY2025 annual figure was $3.2 million, up 35.26% from the prior year.
- Current Deferred Revenue slipped to $2.9 million in Q1 2026 per OABI's latest filing, from $3.2 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $8.2 million in Q4 2022 and bottomed at $983000.0 in Q2 2025.
- Historically, Current Deferred Revenue has averaged $4.3 million across 5 years, with a median of $3.1 million in 2025.
- Annual changes were most pronounced in 2025 — Current Deferred Revenue tumbled 68.79% — and 2026, when it jumped 70.39%.
- OmniAb's Current Deferred Revenue stood at $8.2 million in 2022, then retreated by 16.56% to $6.8 million in 2023, then tumbled by 65.87% to $2.3 million in 2024, then jumped by 35.26% to $3.2 million in 2025, then retreated by 6.96% to $2.9 million in 2026.
- Business Quant data shows OABI's Current Deferred Revenue at $2.9 million in Q1 2026, $3.2 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.30 Mn |
| Mar 31, 2026 | 2.94 Mn |
| Dec 31, 2025 | 3.16 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 983,000.00 |
| Mar 31, 2025 | 1.73 Mn |
| Dec 31, 2024 | 2.34 Mn |
| Sep 30, 2024 | 2.51 Mn |
| Jun 30, 2024 | 2.91 Mn |
| Mar 31, 2024 | 5.53 Mn |
| Dec 31, 2023 | 6.85 Mn |
| Sep 30, 2023 | 7.38 Mn |
| Jun 30, 2023 | 7.27 Mn |
| Mar 31, 2023 | 6.89 Mn |
| Dec 31, 2022 | 8.21 Mn |
| Dec 31, 2021 | 10.79 Mn |